Novartis AG (NYSE:NVS) Stock Has Consensus Target Price of $145.60

by · The Markets Daily

Novartis AG (NYSE:NVS – Get Free Report) has been assigned a consensus rating of “Hold” from the twenty analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $145.60.

A number of analysts have recently weighed in on the stock. Bank of America reiterated a “buy” rating on shares of Novartis in a report on Tuesday, September 8th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, September 17th. Morgan Stanley reiterated an “overweight” rating and issued a $156.00 price objective on shares of Novartis in a report on Tuesday. HSBC raised Novartis from a “reduce” rating to a “hold” rating and boosted their target price for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, September 17th.

Read Our Latest Analysis on Novartis

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. GK Wealth Management LLC purchased a new stake in Novartis in the third quarter worth about $146,000. Wedmont Private Capital grew its holdings in shares of Novartis by 50.8% during the 3rd quarter. Wedmont Private Capital now owns 8,890 shares of the company’s stock worth $1,272,000 after acquiring an additional 2,996 shares during the period. O Keefe Stevens Advisory Inc. raised its position in shares of Novartis by 6.3% in the 3rd quarter. O Keefe Stevens Advisory Inc. now owns 1,460 shares of the company’s stock worth $208,000 after acquiring an additional 87 shares in the last quarter. Diversified Management Inc. bought a new position in shares of Novartis in the 3rd quarter worth approximately $258,000. Finally, First Heartland Consultants Inc. purchased a new position in shares of Novartis in the 3rd quarter valued at approximately $205,000. 13.12% of the stock is currently owned by institutional investors.

Novartis Trading Up 0.4%

Shares of NVS opened at $143.67 on Wednesday. Novartis has a fifty-two week low of $121.57 and a fifty-two week high of $170.46. The firm has a market cap of $274.14 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 2.73 and a beta of 0.41. The firm has a 50 day moving average price of $149.11 and a 200-day moving average price of $150.55. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Novartis (NYSE:NVS – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. As a group, equities research analysts forecast that Novartis will post 8.89 earnings per share for the current year.

Novartis Company Profile

(Get Free Report)

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.

Featured Stories